ASC 618
Alternative Names: Adeno-associated viral vector haemophilia A gene therapy - ASC Therapeutics; ASC-618; CRISPR/cas9 edited human factor VIII - ASC TherapeuticsLatest Information Update: 16 Dec 2024
At a glance
- Originator ASC Therapeutics
- Class Antihaemorrhagics; Blood coagulation factors; Gene therapies
- Mechanism of Action Factor VIII replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Haemophilia A
Most Recent Events
- 11 Dec 2024 Adverse events and efficacy data from a phase I/II trial Haemophilia A released by Expression Therapeutics
- 31 Aug 2022 Phase-I/II clinical trials in Haemophilia A in USA (Parenteral) (NCT04676048)
- 16 May 2022 ASC 618 receives Orphan Drug status for Haemophilia A in Europe prior to May 2022